Advanced Search Help

This is the advanced search info TODO: ADD INFO HERE!

10,000 results.   Bulk download
Searching everything

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells

KO Mcnerney, et al. (2020)
Front Immunol

  • There is no summary for this article.
Medical and Health Science
 Abstract

Antibody-based immunotherapy in high-risk neuroblastoma

E Johnson, SM Dean, PM Sondel (2007)
Expert Reviews in Molecular Medicine

Summary

  • Although great advances have been made in the treatment of low- and intermediate-risk neuroblastoma in recent years, the prognosis for advanced disease remains poor.
  • This article reviews the use of monoclonal antibodies either as monotherapy or as part of a multifaceted treatment approach for advanced neuroblastoma, and explains how toxins, cytokines, radioactive isotopes or chemotherapeutic drugs can be conjugated to antibodies to enhance their effects.
  • Tumour resistance, the development of blocking antibodies, and other problems hindering the effectiveness of monoclonal antibodies are also discussed.
Biology
Chemistry
Medical and Health Science
 Abstract

Immunotherapy. Neuroblastoma as a model.

CN K (1991)
Pediatric clinics of North America

  • There is no summary for this article.
Medical and Health Science
 Abstract

Treatment-Resistant Neuroblastoma Populations after Anti-GD2 Immunotherapy

AK Zamora, et al. (2019)
Journal of the American College of Surgeons

  • There is no summary for this article.
Medical and Health Science
 Abstract

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy

IV Kholodenko, et al. (2018)
Journal of Immunology Research

Summary

  • Only one drug for targeted immunotherapy of neuroblastoma, chimeric monoclonal GD2-specific antibodies, is used in the clinic today, and its application has significant limitations.
  • In this regard, the development of effective and safe GD2-targeted immunotherapies and analysis of other potential molecular targets for the treatment of neuroblastoma represents an important and topical task.
  • The review summarizes biological characteristics of the origin and development of neuroblastoma and outlines molecular markers of neuroblastoma and modern immunotherapy approaches directed towards these markers.
 Abstract

Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma

TV Shamanskaya, et al. (2020)
Pediatric Hematology/Oncology and Immunopathology

  • There is no summary for this article.
Medical and Health Science
 Abstract

Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

EL Williams, et al. (2013)
Clinical Cancer Research

Summary

  • In the Neuro2a model, treatment of established tumor with anti-4-1BB, anti-CD40, or anti-CTLA-4 mAb results in tumor regression and long-term survival in 40% to 60% of mice.
  • This is associated with the generation of survivin-specific T-cell immunity, which again is only shown in the presence of tumor antigen.
  • These data suggest that the combination of antigen and costimulatory mAb may provide effective immunotherapy against neuroblastoma and may be of particular use in the minimal residual disease setting.
Medical and Health Science
 Abstract

396. Development of GD2-Specific Immunoliposomes for Immunotherapy of Neuroblastoma

W Huang, et al. (2016)
Molecular Therapy

  • There is no summary for this article.
Biology
Chemistry
Medical and Health Science
Technology
 Abstract

The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model

BL Soto, et al. (2011)
Cancer Immunology, Immunotherapy

Summary

  • On day 10, some mice received 15 mcg of intravenous immunocytokine for 5 days, mice received 20 mg of peritumoral resveratrol twice a week (starting on day 12) for a total of 5 injections, and a separate group received a combination of both regimens.
  • Blood and primary tumor tissue samples were collected on day 20 for Complete Blood Count and CD45 immunohistochemistry and histology, respectively.
  • When resveratrol and immunocytokine regimens were combined, 61% of the mice receiving this combination therapy resolved their primary tumors and survived without developing metastatic tumors, compared to 15 and 13% receiving resveratrol or immunocytokine alone, respectively.
Medical and Health Science
 Abstract

[Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].

R Rousseau, et al. (2006)
Bulletin du cancer

Summary

  • During the last two decades, improvements in the induction and consolidation treatment phases in patients with high-risk neuroblastoma have not translated into significant increases in survival rates.
  • Efforts to improve outcome have used high-dose chemotherapy with stem cell rescue and more recently, differentiating (retinoids) and antiangiogenic agents.
  • We review here the biological concepts underlying these new approaches and their clinical applications, with a particular emphasis on applications that manipulate the immune system, including monoclonal antibodies, gene-modified tumor cells (vaccines) or immune effectors.
 Abstract